Skip to main content

Alzheimer Disease LMT-01-01-22

Status: Open to Enrollment
Email Us To Enroll

Study Details

View study details on clinicaltrials.gov.

Locations

  • San Francisco

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.

Armen Moughamian
Armen Moughamian
Principal investigator
View Profile

Email Us to Enroll

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?